TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00887354
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously
Study: NCT00887354
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02476448
Drug: Phenazopyridine
Normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally preoperatively and assessed during cystoscopy
Study: NCT02476448
Drug: Sodium Fluorescein
Normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously and assessed during cystoscopy
Study: NCT01903005
Drug: Higher bioavailability BNX sublingual tablets
Normalized name: BNX
DrugBank: Oxybuprocaine (DB00892)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
Study: NCT02645864
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
Study: NCT02645864
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150mg/m\^2 i.v. q2w
Study: NCT00191711
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00743470
Drug: lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir/ritonavir tablet; see arm for intervention description
Study: NCT00743470
Drug: rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rifabutin capsule; see arms for intervention description
Study: NCT03688971
Drug: Omiganan
Normalized name: Omiganan
DrugBank: Omiganan (DB06610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omiganan Topical Gel
Study: NCT03688971
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole Cream
Study: NCT00451230
Drug: cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01074931
Drug: Lopinavir/ritonavir (Kaletra)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study.
Study: NCT04466891
Drug: ZW25 (Zanidatamab)
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT01659502
Drug: TL-118
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Study: NCT04174196
Drug: CC-486
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles
Study: NCT04174196
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with CC-486 and lenalidomide for 6 cycles
Study: NCT00840333
Drug: MP-376 (Levofloxacin solution for Inhalation)
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DOSE BASED ON PATIENTS WEIGHT
Study: NCT04272801
Drug: tamoxifen, letrozole, anastrozole, or exemestane
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
Study: NCT02784340
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 mg Dexamethasone IV drip
Study: NCT02784340
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
Study: NCT02784340
Drug: Saline (IV fluids)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV fluids 500 cc saline infusion
Study: NCT00270387
Drug: Natrecor (nesiritide)
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01778413
Drug: ATRIPLA
Normalized name: Atripla
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005979
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04549467
Drug: Lamivudine 300 MG
Normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental arm
Study: NCT04549467
Drug: Emtricitabine / Tenofovir Disoproxil Pill
Normalized name: emtricitabine / tenofovir disoproxil Pill
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00457626
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Extemporaneous suspension of valsartan, orally.
Study: NCT01092221
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 1 capsule 300 mg, BID
Study: NCT03586973
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib tablet
Study: NCT00373542
Drug: ropinirole CR-RLS
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00946595
Drug: efavirenz/emtricitabin/tenofovir
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1x600/200/245 mg per day (one tablet) between W0 et W98
Study: NCT00946595
Drug: lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 x 200/50 mg (4 tablets) once a day between W0 and W98
Study: NCT03744390
Drug: AG-221
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
Study: NCT00152438
Drug: Oral Micronized Progesterone (Prometrium®)
Normalized name: progesterone Oral Capsule [Prometrium]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
Study: NCT01597739
Drug: JNJ-40346527
Normalized name: JNJ-40346527
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
Study: NCT03585179
Drug: Oral Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take a pill of 250 mg bid for 12 weeks
Study: NCT03585179
Drug: 5% topical tranexamic acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will apply a layer of gel on the affected skin bid for 12 weeks
Study: NCT03585179
Drug: 4% hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will apply a layer of cream on the affected skin once at night
Study: NCT02612246
Drug: GLPG1972 multiple ascending doses
Normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multiple doses, daily for 14 days, oral solution
Study: NCT00716820
Drug: SUNITINIB MALATE
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition.
Study: NCT00165828
Drug: Zonegran
Normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
Study: NCT02141321
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00558818
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clevudine 30 mg qd
Study: NCT02700438
Drug: Glyceryl trinitrate ointment
Normalized name: glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
Study: NCT03415750
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conversion from Mycophenolate mofetil to Everolimus
Study: NCT03415750
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will remain in Tacrolimus + Mycophenolate mofetil
Study: NCT00559273
Drug: Methoxy polyethylene glycol-epoetin beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.2 mcg/kg SC monthly, starting dose
Study: NCT03415750
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04171687
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg tablet
Study: NCT04171687
Drug: Tegoprazan 50 mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg tablet
Study: NCT02937779
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
Study: NCT02750592
Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
Study: NCT00516724
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00516724
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous injection
Study: NCT00516724
Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00516724
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection
Study: NCT00516724
Drug: Paclitaxel + Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection
Study: NCT01784029
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
Study: NCT04551300
Drug: VS-505
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 dosages of experimental drug
Study: NCT04551300
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT00366457
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Study: NCT00366457
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Study: NCT00366457
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
Study: NCT01282073
Drug: Cyclosporin, low dose steroid
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks
Study: NCT02180789
Drug: Tamsulosin OCAS
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00822302
Drug: Reconstituted High Density Lipoprotein
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
Study: NCT00822302
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
Study: NCT01701882
Drug: tenofovir/emtricitabine/rilpivirine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00824044
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
Study: NCT00678119
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An approved drug for the treatment of RCC
Study: NCT01403246
Drug: Lenalidomide; Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTD of lenalidomide given in combination with chlorambucil
Study: NCT05314660
Drug: 38 % silver diamine fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 38% SDF on carious dentine lesions.
Study: NCT00360945
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00360945
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02004626
Drug: Collagenase
Normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.
Study: NCT00559273
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
Study: NCT03461718
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm for sedation.
Study: NCT03461718
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
Study: NCT00002529
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
Study: NCT00002529
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily.
Study: NCT00002529
Drug: toremifene
Normalized name: Toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene 60 mg daily.
Study: NCT00688597
Drug: Duvoglustat
Normalized name: Duvoglustat
DrugBank: Duvoglustat (DB03206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder in a bottle for dissolution in water for oral administration
Study: NCT03539445
Drug: Butylphthalide
Normalized name: BUTYLPHTHALIDE
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
Study: NCT04363346
Drug: FT516
Normalized name: FT516
DrugBank: FT516 (DB15732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
Study: NCT02071901
Drug: eltrombopag olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03539445
Drug: Butylphthalide Placebo
Normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
Study: NCT00716469
Drug: LS11
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LS11 will be given as a one-time IV infusion over 3-5 minutes.
Study: NCT01697111
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest 1mg twice a day (bid)
Study: NCT01263119
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mg warfarin oral dose
Study: NCT00023335
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023335
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02138825
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
Study: NCT00415090
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Switch one of ARV drugs to Nevirapine
Study: NCT00220090
Drug: dexloxiglumide
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03094052
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally (PO)
Study: NCT03094052
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03094052
Drug: Diphenoxylate Hydrochloride/Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01752049
Drug: Topical timolol maleate
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient
Study: NCT00251433
Drug: lapatinib, docetaxel, trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
Study: NCT01195974
Drug: YASMIN
Normalized name: Yasmin
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: YASMIN for 21 days
Study: NCT04276207
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by CSII
Study: NCT03180229
Drug: Granisetron 1 Mg/mL Intravenous Solution
Normalized name: granisetron 1 mg/mL intravenous solution
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 milligram (mg) will use on group Granisetron before 5 min induction